Inclusion completed

A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010)Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols

Cancer type: Melanoma

Phase: II

Principal Investigator: Aamdal Steinar

Country: NO

Keywords: Norway, Oslo University Hospital

Status: Inclusion completed

Link to Clinicaltrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT00162123?term=CA184-025&rank=1